June 7, 2023

Keytruda + chemotherapy before surgery and continued as a single agent after surgery reduced the risk of event-free survival events by 42% versus pre-operative chemotherapy in resectable Stage II, IIIA or IIIB NSCLC – Merck Inc

Merck known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase III KEYNOTE-671 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery (neoadjuvant) and after surgery (adjuvant), for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). After a median follow-up of […]

admin Health 0 2 min read
September 23, 2022

Immuno-oncology treatment pre-surgery safe and effective option for localized non-small cell lung cancer

New study data shows that the immuno-oncology drug, atezolizumab (pronounced  a” te zoe liz’ ue mab, marketed as Tecentriq) is a safe and effective treatment for stage IB-IIIB non-small cell lung cancer patients prior to lung cancer surgery, according to a new study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and […]

admin Health 0 3 min read
September 17, 2022

Deep learning algorithm may streamline lung cancer radiotherapy treatment

Lung cancer, the most common cancer worldwide, is targeted with radiation therapy (RT) in nearly one-half of cases. RT planning is a manual, resource-intensive process that can take days to weeks to complete, and even highly trained physicians vary in their determinations of how much tissue to target with radiation. Furthermore, a shortage of radiation-oncology practitioners and clinics worldwide is […]

admin Health 0 2 min read
February 8, 2022

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at least 1%. Data from the IMpower010 trial were published simultaneously in The […]

admin Health 0 1 min read
November 11, 2021

Lung cancer screening for survivors of head and neck cancer

Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to a secondary analysis of the National Lung Screening Trial (NLST) data.1 The landmark NLST randomized more than 50,000 participants at high risk for lung cancer in a 1:1 ratio to either low-dose […]

admin Health 0 2 min read

Recent Posts

Meta

Categories

Archives

Recent Comments